TOMI Environmental (TOMZ) Q2 2026 earnings review
Triple-Digit Growth Overshadowed by a Radical Corporate Pivot
TOMI delivered a blowout quarter for its legacy business, with revenue accelerating 118% YoY to $2.25M and operating losses shrinking by 78%. However, the core decontamination story is now a sideshow. Management's definitive merger agreement with Carbonium Core represents a drastic pivot into nuclear-grade graphite and lithium production. While operations are rapidly approaching breakeven, the balance sheet remains fragile ($321K cash). The company's survival and transformation now hinge entirely on executing a required $10M concurrent financing for the merger.
🐂 Bull Case
Operating loss compressed to just $244K. With gross margins holding strong at 61.7% and a $2.6M backlog, TOMI is within striking distance of cash-flow neutrality before any merger impacts.
The Carbonium Core merger pegs the combined enterprise value at $180M. If the $10M funding is secured, TOMI taps into explosive macro demand for AI data center energy and defense materials.
🐻 Bear Case
With only $321K in cash, the company lacks the organic capital to fund its aggressive $12M revenue target or scale manufacturing. Financing is mandatory, risking massive dilution.
Pivoting from hospital and food decontamination to nuclear-grade graphite mining introduces severe execution risk and completely abandons the company's established core competency.
⚖️ Verdict: ⚪
Neutral. The legacy business is finally demonstrating the operating leverage management has promised for years. However, investing now is a binary bet on the Carbonium Core merger closing and the successful execution of an entirely unrelated business model.
Key Themes
The Carbonium Core Pivot & Macro Tailwinds
The proposed merger with Carbonium Core completely rewrites the investment thesis. TOMI intends to produce nuclear-grade graphite and lithium, targeting 4th-generation nuclear reactors and AI data centers. Management explicitly ties this to recent US government initiatives (referencing a $3B federal investment for critical minerals). This is a radical shift from environmental services to critical minerals, requiring a $10M financing condition to close.
Capital Equipment Sales Surging
Accelerating. Unlike previous quarters where recurring consumables were the highlight, Q2's massive 118% growth was driven primarily by hardware. Applicator sales exploded to $355K (up from $13K in 25Q2), and total product revenue grew 185% YoY to $1.86M. This indicates a release of previously deferred CapEx by customers.
Service Revenue Growth Contradicts 'Razor/Blade' Narrative
Management heavily promoted their 'razor-and-blade' recurring revenue model, but the data tells a different story. While product sales surged, Service Revenue grew a mere 3% YoY (to $389K). The COO admitted during the call that iHP corporate services took a hit due to a 'production change at a large customer that no longer requires decontamination services.' This customer loss directly contradicts the thesis of sticky, recurring service dependency.
EPA AgriMist Registration Unlocks New Markets
The EPA granted an unconditional registration (label -4) for SteraMist AgriMist. This represents a significant technology validation, allowing direct application on food, greenhouse agriculture, and cannabis up to the day of harvest. This bypasses previous regulatory bottlenecks and directly opens up post-harvest agricultural segments.
Liquidity Remains on a Knife's Edge
Despite a massive reduction in operating losses, TOMI ended the quarter with only $321K in cash. While working capital improved to $1.82M, this balance sheet cannot support aggressive organic scale-up. The company requires a $10M concurrent financing for the merger, leaning heavily on convertible note repricing (reduced to $1.50) and its Equity Line of Credit, ensuring further dilution for common shareholders.
Forward Indicators Showing Momentum
Accelerating. The sales backlog has built consistent momentum, stepping up from $1.6M at the end of FY25, to $1.7M in Q1, $2.2M at the end of Q2, and $2.6M post-quarter. Coupled with $6.2M in booked/expected orders for H2, visibility into near-term revenue is the strongest it has been in two years.
Other KPIs
Stable. While down from 65.7% a year ago, it marks a strong sequential recovery from 50.3% in Q1 2026. Management attributed the sequential expansion to higher revenue volume and an optimal mix of equipment deployments alongside high-margin consumables.
Decreased 10% YoY. Notably, this included approximately $300,000 in one-time legal and advisory fees related to the Carbonium Core merger. Excluding these costs, core operational SG&A leverage was exceptionally strong, allowing the 118% revenue jump to flow cleanly to the bottom line.
Guidance
Accelerating. This requires massive execution in the second half. With $3.9M delivered in H1, TOMI must generate over $8.1M in H2 (averaging >$4M per quarter) to hit this target. This implies that Q3 and Q4 must essentially double the already strong Q2 result. Management points to $6.2M in booked/expected completions before year-end as the bridge.
Key Questions
The Implied H2 Steep Ramp
Your $12M full-year guidance requires over $8.1M in revenue in the second half of the year. Given that Q2 was a blowout at $2.25M, what specifically drives the sequential step-up to a ~$4M run rate in Q3/Q4?
Carbonium Core Synergies
Other than public market access, what are the operational synergies between a biological decontamination company and a nuclear-grade graphite producer? How will management split focus between these vastly different businesses?
Contingency for $10M Financing
The Carbonium merger requires a concurrent $10M financing. Given current market conditions and the company's $321K cash balance, what is the contingency plan for the legacy SteraMist business if this financing cannot be secured on favorable terms?